Sign in
Taking people in South KoreaNo phase

Long-term study of Ezefeno added to statin for high cholesterol and diabetes

Tests Ezefeno with a statin in adults with high cholesterol and type 2 diabetes.

Key facts

Who runs it
Korea University Anam Hospital
Where
Seoul, South KoreaSee the site
Trial code
Registry title
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Status
Recruiting
People taking part
3,958 people, planned
Started
1 Mar 2024
Expected to end
1 Feb 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
  • Dose escalation of moderate-intensity statin
Record updated
27 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and high blood fats who are not well controlled on a moderate-intensity statin and have a heart or vessel risk factor.

Age
19 years or older
Sex
Women and men can join.
Disease stage
Type 2 diabetes with high blood fats: non-HDL-C 100 mg/dL (2.6 mmol/L) or more and TG 200 mg/dL (5.2 mmol/L) or more but under 500 mg/dL (12.9 mmol/L), on a moderate-intensity statin.
Earlier treatment
Must be taking a moderate-intensity statin.
Biomarker or test result
Non-HDL-C ≥100 mg/dL (2.6 mmol/L) and TG ≥200, <500 mg/dL.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Uncontrolled high blood sugar (more than 12.0% for people on diabetes treatment)
  • Muscle disease (myopathy) or rhabdomyolysis
  • AST/ALT more than 3 times the upper limit of normal
  • Genetic disorders such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with type 2 diabetes diagnosed by American Diabetes Association criteria
  • Age ≥ 19 years
  • Non-HDL-C ≥100 mg/dL, TG ≥200, <500 mg/dL on moderate-intensity statins
  • with cardiovascular risk factor

Who cannot take part

  • Uncontrolled hyperglycemia(more than 12.0% for Subject treated with anti-diabetic treatment.)
  • AST/ALT more than 3 ULN
  • Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and/or glucose-galactose malabsorption
  • Pregnant or breastfeeding women
  • Patient with myopathy and rhabdomyolysis

Where in South Korea

  • Korea University Anam HospitalSeoul, South KoreaContact: Sin Gon Kim, MDTaking people

About the trial

What the trial wants to find out

The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:

Read full original descriptionShow less

* major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration

The 2 groups in the trial

  • Treatment groupTreatment being tested

    Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

    Treatment: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

  • Control groupExisting treatment, for comparison

    Dose escalation of moderate-intensity statin

    Treatment: Dose escalation of moderate-intensity statin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
To Assess the Long-term Efficacy and Safety of Combined Therapy With Ezefeno Tab. in Patients With Dyslipidemia Who do Not Achieve Adequate Control of Non-HDL-C Levels Even With Moderate-intensity Monotherapy
Plain-language title
Long-term study of Ezefeno added to statin for high cholesterol and diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
27 August 2024